Abstract
Hepatitis C virus infection is associated with increased morbidity and mortality.
It remains a major challenge for management and treatment, especially in patients
with renal transplant. The new directacting antiviral agents gave big hopes to both
clinicians and patients that they can overcome this challenge without major side effects.
Studies recently have supported this claim; however, they are still few, limited,
and may give false hopes. In the following case report, we present a case, supported
by histological evidence about a possible acute rejection of kidney transplant after
treatment with these new medications. This case is limited by the absence of donorspecific
antibodies. This report is aimed to increase awareness about the urgent need for further
studies.
Keywords
Acute rejection - anti-hepatitis C virus medication - daclatasvir - direct-acting
antiviral agents - kidney transplant - sofosbuvir
